EpiBone

EpiBone is a biomedical engineering company focused on regenerative medicine and tissue engineering. Founded in New York City in 2013 by Nina Tandon and Sarindr “Ik” Bhumiratana, the company emerged from research conducted at Columbia University into the engineering of bone and osteochondral tissues. Its central approach is to use a patient’s own mesenchymal stem cells as the biological starting material for creating tissue outside the body. The company’s work is directed toward bone-graft applications. Rather than relying solely on conventional graft material, EpiBone’s platform is intended to produce living, patient-specific tissue that could be used to repair or replace damaged bone. The process described in reference material involves developing bone tissue in vitro, with the resulting tissue potentially serving as a graft. This places EpiBone within the broader fields of regenerative medicine, orthopedic biotechnology, cell-based therapies, and tissue engineering. EpiBone’s origins are closely connected to academic research at Columbia University, where the founders worked on methods for engineering bone and osteochondral tissue. The company was established to advance that research toward biomedical applications. Publicly available reference material identifies its technology and founding history but does not provide sufficient information to establish the company’s current commercial status, approved products, clinical milestones, financing history, ownership structure, or geographic operating footprint. The company’s positioning is therefore best understood as research-driven regenerative medicine rather than as a conventional consumer-facing product brand. Its proposed value lies in combining autologous cell sourcing with engineered tissue production, with the aim of developing grafts that are biologically compatible with individual patients. The available material does not confirm whether any EpiBone product has received regulatory approval or entered routine clinical use.

EpiBone was founded in 2013 in New York City by Nina Tandon and Sarindr “Ik” Bhumiratana. Its origins lie in research at Columbia University concerning the engineering of bone and osteochondral tissue. The founders’ work addressed the possibility of creating replacement biological tissues outside the body rather than depending exclusively on donated or synthetic graft materials. The company’s technology is described as using mesenchymal stem cells obtained from an individual patient. These cells serve as the basis for developing bone tissue in vitro, with the intended result being a graft suitable for bone-repair applications. The approach reflects a broader shift in regenerative medicine toward tissue constructs that are biologically active and potentially matched to a specific patient. EpiBone’s stated area of development includes bone tissue and, by connection with its founding research, osteochondral tissue engineering. Bone grafting is the principal application identified in the available reference material. However, the cited material does not establish later clinical-trial results, regulatory approvals, commercial product launches, partnerships, acquisitions, ownership changes, or the company’s present operating status. Consequently, EpiBone’s documented history remains centered on its 2013 founding and its Columbia University-derived scientific program.

• 2013

  EpiBone is founded

  [1]EpiBoneen.wikipedia.org

  Nina Tandon and Sarindr “Ik” Bhumiratana founded EpiBone in New York City to develop tissue-engineering technologies derived from research at Columbia University.

Research-driven regenerative medicine company focused on patient-specific bone and osteochondral tissue engineering.

• Regenerative medicine

  Patient-specific engineered bone tissue

  EpiBone is developing a method to create bone tissue outside the body using mesenchymal stem cells taken from the patient. The resulting tissue is intended for use in bone-graft procedures, potentially offering a biologically matched alternative to conventional graft materials. The available reference does not confirm a commercial launch, regulatory authorization, or routine clinical availability.

• Tissue engineering

  Engineered osteochondral tissue

  The company’s founding research at Columbia University included bone and osteochondral tissue engineering. This represents the broader scientific context for EpiBone’s regenerative-medicine platform, although the available source does not identify a separately launched osteochondral product or establish its current development stage.

1. 1EpiBoneen.wikipedia.org